Skip to content

Effect of green coffee poly cystic ovary syndrome

The effect of Green Coffee compared with placebo supplementation on paraoxonase-1 activity and malondialdehyde levels in patient of poly cystic ovary syndrome

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191129045540N1
Enrollment
40
Registered
2020-02-13
Start date
2019-12-31
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: A natural product prepared from 400 mg green coffee bean extract powder with 50% chlorogenic acid basis and low caffeine(2%) and lactose. one tablet in a day. Bonya

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women with polycyctic ovary syndrom who tend to participate in research Age range of 20-40 years old

Exclusion criteria

Exclusion criteria: Pregnancy decision during the study period Having a allergy and intolerance to Green Coffee supplement Taking steroidal and non-steroidal anti-inflammatory drugs The precence of thyroid and kidney disorders Consumption of nutritional supplement other than calcium, iron and folic acid

Design outcomes

Primary

MeasureTime frame
Paraoxonase-1 level. Timepoint: At the begining and at the end of the study (after 40 days). Method of measurement: ELISA.;Malondialdehyde level. Timepoint: At the begining and at the end of the study (after 40 days). Method of measurement: ELISA.

Secondary

MeasureTime frame
Cholestrol. Timepoint: At the beginning of and at the end of study (after 40 days). Method of measurement: Auto Anelyzer.;Triglycerid. Timepoint: At the begining and at the end of study (after 40 days). Method of measurement: Auto anelyzer.;LDL. Timepoint: At the begining and at the end of study(after 40 days). Method of measurement: Auto anelyzer.;HDL. Timepoint: At the begining and at the end of study(after 40 days). Method of measurement: Auto anelyzer.;Fasting blood glucose. Timepoint: At the begining and at the end of study(after 40 days). Method of measurement: Auto anelyzer.;Insulin. Timepoint: At the begining and at the end of study(after 40 days). Method of measurement: Elisa.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzam Ildarabadi

Islamic Azad University

azam.ildarabadi@srbiau.ac.ir+98 21 7737 8101

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026